Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
2.828 CHF | +9.95% | +32.89% | +33.77% |
28.03. | Aktien Schweiz Schluss: SMI geht mit kleinem Plus ins Osterwochenende | AW |
25.03. | Morning Briefing - Markt Schweiz | AW |
Kurzporträt
Mitarbeiterzahl: 650
Umsatz nach Geschäftsbereich
CHF in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Drugs
100,0
%
| 35 | 100,0 % | 97 | 100,0 % | +174.70% |
Umsatz je Region
CHF in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Switzerland
48,0
%
| 35 | 100,0 % | 47 | 48,0 % | +31.77% |
Japan
45,3
%
| - | - | 44 | 45,3 % | - |
United States
5,7
%
| - | - | 6 | 5,7 % | - |
Rest of World
1,0
%
| 0 | 0,0 % | 1 | 1,0 % | - |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 68 | 01.06.17 |
André Muller
DFI | Director of Finance/CFO | 60 | 01.06.17 |
Guy Braunstein
CTO | Chief Tech/Sci/R&D Officer | 67 | 03.03.17 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 01.06.17 |
Andrew C. Weiss
IRC | Investor Relations Contact | 55 | 01.06.17 |
Alberto Gimona
PRN | Corporate Officer/Principal | 64 | 01.02.19 |
Julien Gander
LAW | General Counsel | 45 | - |
Human Resources Officer | 45 | 01.06.17 | |
Simon Jose
PRN | Corporate Officer/Principal | 58 | 01.12.18 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 13.05.20 |
Peter Kellogg
BRD | Director/Board Member | 68 | 12.05.21 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 68 | 01.06.17 |
Felix R. Ehrat
BRD | Director/Board Member | 67 | 13.05.20 |
Sandy Mahatme
BRD | Director/Board Member | 59 | 13.05.20 |
Mathieu Simon
CHM | Chairman | 67 | 03.05.19 |
Srishti Gupta
BRD | Director/Board Member | 47 | 12.05.21 |
Director/Board Member | 61 | 04.05.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 188 574 316 | 110 632 218 ( 58,67 %) | 9 653 500 ( 5,119 %) | 58,67 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
IDORSIA LTD 4,80% | 9 049 500 | 4,80% | 22 938 492 $ |
1 301 128 | 10,31% | 15 367 363 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. |
Pharmaceuticals: Major
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+33.77% | 507 Mio. | |
+2.73% | 108 Mrd. | |
+9.59% | 104 Mrd. | |
+6.58% | 23.66 Mrd. | |
-12.59% | 22.1 Mrd. | |
-3.29% | 19.71 Mrd. | |
-35.36% | 18.2 Mrd. | |
-13.29% | 16.19 Mrd. | |
+4.68% | 13.72 Mrd. | |
+34.25% | 12.22 Mrd. |
- Börse
- Aktien
- Aktie Idorsia Ltd - Swiss Exchange
- Unternehmen Idorsia Ltd